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Abstract
Objective: The liver X receptor a (LXRa) is a ligand-dependent nuclear receptor and the major regulator of reverse
cholesterol transport in macrophages. This makes it an interesting target for mechanistic study and treatment of
atherosclerosis.
Methods and Results: We optimized a promising stilbenoid structure (STX4) in order to reach nanomolar effective
concentrations in LXRa reporter-gene assays. STX4 displayed the unique property to activate LXRa effectively but not its
subtype LXRb. The potential of STX4 to increase transcriptional activity as an LXRa ligand was tested with gene expression
analyses in THP1-derived human macrophages and oxLDL-loaded human foam cells. Only in foam cells but not in
macrophage cells STX4 treatment showed athero-protective effects with similar potency as the synthetic LXR ligand
T0901317 (T09). Surprisingly, combinatorial treatment with STX4 and T09 resulted in an additive effect on reporter-gene
activation and target gene expression. In physiological tests the cellular content of total and esterified cholesterol was
significantly reduced by STX4 without the undesirable increase in triglyceride levels as observed for T09.
Conclusions: STX4 is a new LXRa-ligand to study transcriptional regulation of anti-atherogenic processes in cell or ex vivo
models, and provides a promising lead structure for pharmaceutical development.
Citation: Feldmann R, Geikowski A, Weidner C, Witzke A, Kodelja V, et al. (2013) Foam Cell Specific LXRa Ligand. PLoS ONE 8(2): e57311. doi:10.1371/
journal.pone.0057311
Editor: Antonio Moschetta, University of Bari & Consorzio Mario Negri Sud, Italy
Received August 22, 2012; Accepted January 21, 2013; Published February 25, 2013
Copyright:  2013 Feldmann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported by the BMBF (grant number 0315082), the NGFN (grant number 01 GS 0828), the European Union (FP7/2007–2013], under grant
agreement nu 262055 (ESGI)), and the Max Planck Society. The financial support from the Hochschuljubila¨umsstiftung of the City Vienna (project number H2158/
2010) is greatly appreciated for the synthetic part of the study (T.S.). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sauer@molgen.mpg.de
Introduction
Atherosclerosis and cardiovascular diseases have become
enormous health problems during the last decades. Macrophages
play a pivotal role in the development and progression of
atherosclerosis [1]. A key event of atherosclerosis involves the
uncontrolled uptake of oxidized low density lipoproteins (oxLDL)
in macrophages, which agglomerate at the subendothelial space of
blood vessel walls [2]. When macrophages fail to restore their
cellular cholesterol homeostasis via regulate reverse cholesterol
transport (RCT) they form diseased foam cells, main components
of fatty streaks [3]. The ligand-depend transcription factors LXRa
and LXRb act as cholesterol sensors and respond to elevated
oxysterol levels by activating target genes with impact on
cholesterol metabolism and atherosclerosis [4]. Many approaches
have been pursued to identify a promising LXR ligand with
exclusively beneficial properties [5,6]. Unfortunately, LXRs are
also implicated in other counteracting physiological processes,
such as triglyceride synthesis [7]. A current challenge is to develop
powerful and selective LXR modulators as biochemical tools for
mechanistic studies on LXR biology, and to provide pharmaceu-
tically exploitable compounds without mentioned adverse side-
effects [8].
While in the past selective agonists for the ubiquitously
expressed subtype LXRb showed in general low efficiency to
counteract atherogenic processes, recent evidence suggests that
rather the LXRa subtype plays a crucial role for regulating anti-
atherogenic gene expression profiles [9]. In human macrophages
LXRa is regulated via a feed-forward autocatalytic loop leading to
significantly increased levels by LXRa ligand-treatment [10]. In
mouse macrophages this effect was not observed, indicating that
activation in human foam cells differs strongly from mouse foam
cells.
Here we introduce an LXRa ligand that specifically activates
target genes in diseased human foam cells but not in macrophages.
This activation resulted in significant reduction of total and
esterified cholesterol with similar potency as for the synthetic
LXRa/b ligand T0901317 (T09) - without the observed counter-
acting increases of triglyceride levels known from previously
published LXRa/b ligands.
Materials and Methods
LXRa Ligand Screening
We used the LXR alpha coactivator kit (Invitrogen) and
screened a biologically diverse library of .7,000 compounds for
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nanomolar binders according to manufacturer’s instructions.
T0901317 (T09) was obtained from Sigma-Aldrich.
STX4 Ligand Synthesis
All chemicals were obtained from commercial suppliers and
used without further purification. 1H and 13C NMR spectra were
recorded on a Bruker Advance DP6200. Chemical shifts values
are reported in ppm relative to Me4Si. TLC was performed on
MERCK silica gel TLC aluminium sheets with fluorescent
indicator 254 nm. Elemental analysis was performed on a Perkin
Elmer 2400 CHN Elemental Analyzer at the microanalytical
laboratory of the University of Vienna. Mass spectra were
performed on a Shimadzu (GC-17A; MS-QP5050A) spectrome-
ter.
For synthesis of 4-[(E)-styryl]phenol (compound 1) we used
a mixture of 4-hydroxybenzaldehyde (0.244 g; 2.00 mmol), phenyl
acetic acid (0.272 g; 2.00 mmol) and piperidine (catalytic amount)
and heated all at 240uC for 15 minutes. After cooling to room
temperature 40 ml of ethyl acetate was added. The organic phase
was washed with water and dried with sodium sulfate. The solvent
was evaporated under reduced pressure and the product purified
by chromatography (petroleum ether/ethyl acetate 8:2) to obtain
title compound as white solid.
Mp: 184–186uC; Yield: 31.6%; 1H NMR (d6-DMSO,
200 MHz): d 6.71–6.88 (m, 2H, ArH), 6.94–7.63 (m, 9H, ArH),
9.30–9.88 (bs, 1H, OH). 13C NMR (d6-DMSO, 50 MHz): d 115.6
(2C, CH), 125.1 (1C, CH), 126.0 (2C, CH), 127.0 (1C, CH), 127.9
(2C, CH), 128.1 (1C, Cq), 128.4 (1C, CH), 128.6 (2C, CH), 137.5
(1C, Cq), 157.3 (1C, Cq). Anal. Calcd. for C14H12O: C, 85.68; H,
6.16. Found: C, 85.59; H, 5.97. MS m/z 196 (100%, M+), 195
(39%), 177 (31%), 165 (32%).
For further synthesis of 2-[[4-[(E)-styryl]phenoxy]methyl]oxir-
ane (STX4) we used a suspension of compound 1 (0.196 g;
1.00 mmol) and NaOH (0.048 g; 1.20 mmol) in epichlorohydrin
was heated at 130uC for 6 hours. The mixture was then
evaporated under reduced pressure and redissolved in diethyl
ether. The precipitate was filtered off and the filtrate was washed
with water. The organic layer was dried over sodium sulfate and
evaporated under reduced pressure. The dried product was
recrystallized from ethanol.
Mp: 133–135uC; Yield: 50.4%; 1H NMR (CDCl3, 200 MHz):
d 2.72–3.01 (m, 2H, CH2), 3.28–3.50 (m, 1H, CH), 3.90–4.35 (m,
2H, CH2), 6.84–7.15 (m, 4H, Ar H), 7.20–7.64 (m, 7H, Ar H).
13C
NMR (CDCl3, 50 MHz): d 44.9 (1C, CH2), 50.2 (1C, CH), 68.9
(1C, CH2), 115.0 (2C, CH), 126.4 (2C, CH), 127.1 (1C, CH),
127.4 (1C, CH), 127.9 (2C, CH), 128.2 (1C, CH), 128.8 (2C, CH),
Figure 1. STX4 is a novel selective LXRa agonist. A, Chemical structure of STX4. B, Transcriptional activation of LXRa by T0901317 (T09), 22-R-
hydroxycholesterol or STX4 in a reporter gene assay (see also Table 1). Data are expressed as mean6SD (n = 3). C, Validation of LXRa specificity.
Transcriptional activation of LXRb by T09 or STX4 in a reporter gene assay. STX4 does not activate the LXRb subtype (mean6SD, n = 3). D, Cytotoxicity
of STX4 in macrophages (mean6SD, n= 3). STX4 does not reduce cellular viability up to 25 mM.
doi:10.1371/journal.pone.0057311.g001
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Figure 2. STX4 specifically targets diseased, oxysterol-loaden foam cells. A, Gene expression in foam cells after siRNA-mediated, single and
combined LXRa/b knockdown (mean6SEM, n = 4, fold-change vs. DMSO, logarithmised). Left, efficiency of LXRa, LXRb and LXRa/b knockdown (kd).
Middle, LXRa, LXRb and LXRa/b knockdown (kd). Middle, single and combined knockdown influence on gene expression of LXRa, LXRb and ABCA1
upon T09 treatment. Right, single and combined knockdown influence on gene expression of LXRa, LXRb and ABCA1 upon STX4 treatment. *P,0.05,
LXRa Ligand
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130.8 (1C, Cq), 137.7 (1C, Cq), 158.3 (1C, Cq). Anal. Calcd. for
C17H16O2: C, 80.93; H, 6.39. Found: C, 80.90; H, 6.17. MS m/z
252 (100%, M+), 196 (49%), 195 (44%), 165 (43%), 152 (40%).
Cell Culture
We used the human THP1 cell line, which is widely applied as
a macrophage and foam cell model with similar properties as
primary cells [11]. THP-1, a human acute monocytic leukemia
cell line, was obtained from Deutsche Sammlung von Mikroorga-
nismen und Zellkulturen (DSMZ) and cultivated at 37uC (5%
CO2, 95% humidity) in RPMI 1640 (Invitrogen) supplemented
with 10% FBS Superior (Biochrom). For generating macrophages
differentiation was induced by 1028 M Phorbol 12-myristate 13-
acetate (PMA) (Sigma-Aldrich) for 48 h. Ligand treatment of
macrophages was performed for further 24 h. To induce foam cell
formation macrophages were treated for additional 48 h with
100 mg/mL modified human oxidized low density lipoprotein
(oxLDL) obtained from Source BioScience (RP-048). Ligand
treatment was performed simultaneously with foam cell formation.
Cholesterol loading and treatment was controlled with Oil Red O
staining (Alfa Aeser). To investigate ligand induced effects on cell
proliferation of THP-1 macrophages CellTiter-Glo Luminescent
Cell Viability Assay (Promega) was utilized.
For dual luciferase reporter gene assay we used human
embryonic kidney (HEK-293) cells that were cultivated in
Dulbeccos Modified Eagle Medium (DMEM) with 4,5 g/L
glucose (Invitrogen) and 10% FBS Superior at 37uC (5% CO2,
95% humidity).
Plasmid Cloning and Dual Luciferase Reporter Gene
Assay
The ligand binding domain (LBD) of LXRa (amino acids 164 to
447) or LXRb (amino acids 154 to 461) was cloned into pBIND
[Renilla/Amp] vector (Promega). Selection and amplification
were performed in E. coli cells. Purification of the plasmids was
performed with a plasmid purification kit (Qiagen). For trans-
fection HEK-293 cells were plated in 96-well plates (TPP) at
a density of 3.56104 cells/well for 24 h. To investigate the ligand
binding on LXRa ligand binding domain, 0.04 ng of renilla
luciferase coding plasmide pGL4.75 (Promega), 0.04 ng of LXRa-
LBD/GAL4-DBD plasmide and 80 ng of firefly luciferase coding
plasmide pGL4.31 (Promega) were used in a total volume of
200 mL for each well. For LXRb binding assay 40 ng of LXRb-
LBD/GAL4-DBD plasmide were applied in each transfection
mix. Transfection was carried out for 4 h with Lipofectamine 2000
Transfection Reagent (Invitrogen) in Opti-MEM medium (Invi-
trogen). Ligand treatment was performed at different concentra-
tions for 24 h. For lysis and detection dual-luciferase reporter gene
assay system (Promega) and POLARstar Omega (BMG LAB-
TECH) were used.
LXR Knockdown
Target specificity of ligand-dependent gene expression effects
was investigated in siRNA-mediated LXRa and b-knockdown
foam cells with subsequent qPCR or microarray analysis.
Therefore, 26105 THP-1 cells/well were differentiated in 24-well
plates and induced to foam cells prior to knockdown as described
above. Foam cells were transfected using TransIT-TKO trans-
fection reagent (Mirus Bio), for combined knockdown with 15 nM
LXRa Silencer Validated siRNA (Ambion, ID 5458) and 15 nM
LXRb Silencer Select Validated siRNA (Ambion, ID s14684) and
with 30 nM LXRa or LXRb for individual knockdowns, re-
spectively. As control we used 30 nM Silencer Select Negative
Control #1 (Ambion). Transfection was carried out for 48 h and
followed by treatment with 10 mM ligand or vehicle control for
24 h.
Real-time Polymerase Chain Reaction
Total RNA isolation and purification was performed by using
the RNeasy Mini Kit (QIAGEN) and RNase-Free DNase Set
(QIAGEN). cDNA was generated by reverse transcription using
the High Capacity cDNA Reverse Transcription Kit (Life
Technologies). Gene expression was quantified using the SYBR
Green PCR Master Mix (Life Technologies) and ABI 7900HT
Fast Real Time PCR System (Life Technologies). In each reaction
0.8 ng/mL cDNA and 0.2 mM primers were used. Gene expres-
sion was calculated with the DDCt-method. ß-Actin was used for
normalisation.
Microarray Analysis
Microarray analyses were performed according to instructions
of Illumina‘s TotalPrep RNA Amplification Kit followed by
hybridisation on HumanHT-12 v3 or HumanHT-12 v4 Expres-
sion BeadChips (Illumina). Data analysis was performed with
GenomeStudio V2011.1 (Illumina). Differential expression analy-
sis was performed on background-subtracted data with cubic
spline normalization and Benjamini-Hochberg FDR correction.
Significant data was considered to have a detection p-value of
#0.01 and differential expression p-value of #0.05 according to
Illumina’s t-test error model. Gene expression data were submitted
in MIAME-compliant form to the NCBI Gene Expression
Omnibus database (GSE39079) [12]. Bead array data were
validated by quantitative real-time PCR. The Gene Distance
Matrix was conducted in Euclidean space using the MeV 4.3
software tool [13]. Gene Set Enrichment Analysis (GSEA) was
performed as described elsewhere [14] with the following
parameters: 1000 gene set permutations, weighted enrichment
**P,0.01, ***P,0.001 vs. negative siRNA. B, Gene expression in THP-1 macrophages and foam cells after treatment with T09 (10 mM) or STX4
(10 mM). Data are expressed as mean6SEM (n= 4). C, Western blot analysis of LXRa and APOE content in foam cells and STX4 treated foam cells. Bar
plot displays the results of densitometry analysis (mean6SEM, n = 3). *P,0.05, **P,0.01 vs. foam cell.D, Transcriptional activation of LXRa by STX4 in
the presence or absence of 200 nM T09 (see also table 1). Data are expressed as mean6SD (n = 3). E, Gene expression in THP-1 macrophages after
treatment with different concentrations of T09 or STX4 in the presence or absence of 1 mM T09. Data are expressed as mean6SEM (n = 2–3). *P,0.05,
**P,0.01, ***P,0.001 vs. DMSO; n.s., not significant.
doi:10.1371/journal.pone.0057311.g002
Table 1. Results from competitive reporter-gene assays.
Compound +DMSO
+200 nM T0901317
(additive)
EC50 Efficacy EC50 Efficacy
(range)
T0901317 239 nM 100%
22-R-Hydroxycholesterol 13.3 mM 4%
STX4 35 nM 6% 28 nM 47%
(64 to 111%)
doi:10.1371/journal.pone.0057311.t001
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statistics, minimal gene set size of 5, and signal-to-noise metric.
Enrichment of pathways was tested using the Reactome (v3.0) and
the KEGG (v3.0) database from the Molecular Signature
Database (MSigDB). Heatmaps were carried out with Mayday
2.8 [15]. For presentation of treatment effects in the heatmap, the
pathway normalized enrichment score (NES) was adjusted with
the appropriate FDR as follows: adjustedNES= (12FDR)6NES.
Western Blotting
Whole cell extracts were harvested from three biological
replicates and denaturized for SDS-PAGE (NuPAGE Novex 4–
12% Bis-Tris Gels). Proteins were blotted on nitrocellulose
Hybond ECL membrane and incubated with strictly validated
published antibodies against LXRa (Abcam, ab 41902), APOE
(Abcam ab1906), and as housekeeping protein control b-Actin
(Santa Cruz Biotechnology, sc-47778, C4). Secondary antibodies
were HRP labeled anti-mouse and anti-rabbit (Santa Cruz
Biotechnology). After detection with Western Lightning Plus-
ECL solution membranes were stripped with Restore Plus
Western Blot Stripping Buffer. Densitometry was performed in
ImageQuant TL (GE Healthcare). This tool measures quantita-
tively the optical density and provides more accurate data than
simple eye-observations. The calculation of log (protein of
interest/b-Actin) corrects data for loading imbalances.
Cholesterol and Triglyceride Analyses
THP-1 monocytes were plated out into 24-well plates (Nunc) at
a density of 26105 cells/well. After differentiation and treatment
cells were lysed with 100 mL lysis buffer (PBS, 0.25 M NaCl, 1%
Triton X-100). Total and free cholesterol were determined using
the colorimetric enzymatic Amplex Red Cholesterol Assay Kit
(Invitrogen). Triglycerides were quantified by Triglyceride Assay
Kit (BioVision). For normalisation protein content was determined
with Pierce 660 nm Protein Assay Reagent (Thermo Scientific).
Figure 3. STX4 specifically regulates gene expression in foam cells. A, Genome-wide gene expression and subsequent gene set enrichment
analysis (GSEA) of macrophages and foam cells after treatment with T09 (10 mM) or STX4 (10 mM). Regulation of lipid-derived Reactome and KEGG
pathways is shown. B, Validation of gene expression microarray analysis by quantitative PCR. For all tested samples, array observations significantly
correlated with qPCR results. C, Gene distance matrix of genome-wide gene expression analysis of macrophages and foam cells after treatment with
DMSO (0.1%), T09 (10 mM) or STX4 (10 mM). Pairwise distances were calculated for comparison of two treatments and cell types. Colored squares
show the distance in Euclidean space, ranging from exactly the same profile (black) to completely different (red). In macrophages STX4 expression is
very different to that of T09 (P,0.0001), whereas in foam cells STX4-induced gene expression is similar to that of T09 (P,0.0001).
doi:10.1371/journal.pone.0057311.g003
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Statistical Analyses
Statistical significance was determined by unpaired two-tailed
Student’s t-test for single comparisons and one-way ANOVA with
Dunnett’s post-hoc test for multiple comparisons. Statistical
analyses were carried out using GraphPad Prism 5.0. A p-value
#0.05 was defined as statistically significant.
Results
During the screening of a natural products library [16], we
identified the stilbenoid backbone as a suitable candidate structure
for activating LXR. Thereby, we observed an increased activation
potential of stilbenoids with an epoxide (STX4, Figure 1A). To
analyse binding and activation ability of the new ligand STX4 we
applied dual luciferase reporter-gene assays with LXRa and
LXRb ligand binding domains (LBD) in HEK-293 cells (Figure 1B
and Figure 1C). Whereas the control ligand T09 bound to LXRa
and LXRb with similar affinity, STX4 showed characteristic
specificity for LXRa (EC50 = 35 nM) but less efficient transcrip-
tional activation (6% vs. T09). We additionally measured the
LXRa activation potential of the natural ligand 22-R-Hydro-
xycholesterol (EC50 = 13.3 mM, Figure 1B) and observed even
lower transcriptional activation (4% vs. T09).
As for T09, viability assays revealed no cytotoxic effects of
STX4 up to 50 mM (Figure 1D), making this compound suitable
for cell culture studies.
To test for ligand specificity we performed LXRa and LXRb
knockdown experiments (Figure 2A). For the T09 ligand we
detected in absence of both subtypes a significant reduction of
LXRa and ABCA1 expression, whereas STX4 treatment showed
a higher dependency on the LXRa subtype. Notably, the STX4
knockdown study was less robust than with T09 due to apparent
cross-reactivity of STX4 with the transfection reagent. However,
consistent with the above described reporter gene assays we
observed in foam cells higher LXRa than LXRb specificity of
STX4.
For testing the activation of LXRa in human macrophages and
in diseased human foam cells we performed gene expression
analyses of central LXRa target genes (namely LXRa itself,
SREBF1, ABCA1, and APOE in Figure 2B). In macrophages we
observed increased expression of LXRa target genes upon T09
treatment, but not with STX4. Strikingly, in foam cells STX4
treatment resulted in potent target gene expression similar to T09,
Figure 4. Physiological analyses of STX4 treatment confirm unique STX4 properties in foam cells. A, Cholesterol content in foam cells
after treatment for 48 h with DMSO (0.1%), T09 (10 mM) or STX4 (10 mM). Data are expressed as mean6SEM (n = 5–6). B, Cholesterol content in
macrophages after treatment for 48 h with DMSO (0.1%), T09 (10 mM) or STX4 (10 mM). Data are expressed as mean6SEM (n= 5–6). C, Triglyceride
content in foam cells after treatment for 48 h with DMSO (0.1%), T09 (10 mM) or STX4 (10 mM). D, Triglyceride content in macrophages after
treatment for 48 h with DMSO (0.1%), T09 (10 mM) or STX4 (10 mM). Data are expressed as mean6SEM (n= 5–6). ***P,0.001 vs. DMSO; n.s., not
significant.
doi:10.1371/journal.pone.0057311.g004
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which was consistent with increased protein expression levels of
LXRa target genes (Figure 2C).
In a competitive reporter-gene assay with a fixed concentration
of T09 and increasing levels of STX4, we detected additive effects
on reporter gene activation (efficacy range 64%–111%, Figure 2D,
Table 1) and ABCA1 expression in macrophages (Figure 2E),
indicating conditional activation potency of STX4 in foam cells.
These data suggest that activation of LXRa upon STX4 treatment
occurred selectively under the diseased condition of the foam cell.
To study the genome-wide effects of STX4 treatment we
performed microarray-based expression analyses on STX4-, T09-
or DMSO-treated macrophages and foam cells (Figure 3A).
Consistent with qPCR data (Figure 3B), expression of genes
involved in lipid metabolism processes was activated in T09-
treated but not in STX4-treated macrophages. However, in foam
cells we found a high similarity between STX4 and T09 treatment
(Figure 3C). Lipid metabolism processes were comparably up-
regulated by T09 and STX4 in foam cells (Figure 3A), which
consequently resulted in a significant reduction of total and
esterified cholesterol content in contrast to macrophage treatments
(Figure 4A and Figure 4B).
Interestingly, we noted a difference between T09 and STX4
treatments in terms of triacylglyceride biosynthesis. While this
process was transcriptionally induced by T09 treatment, it was not
regulated by STX4 treatment in foam cells (Figure 3A). Consis-
tently, treatment with T09 but not STX4 led to increased
triglyceride levels in foam cells (Figure 4C). In macrophages the
triglyceride level stayed rather unchanged for both treatments
(Figure 4D).
Notably, despite the observed up-regulation of SREBF1 mRNA
in STX4-treated cells (Figure 2B), which is a common marker gene
for lipogenesis, triglyceride levels were not increased. This example
illustrated the strength of the applied gene set enrichment analysis
method to decipher functional pathways and explain complex
effects of nuclear receptor ligands compared to limited information
from conventional single gene centered assessments. Further
studies are needed to explore the observed effects. Anyway, the
LXRa agonist STX4 featured a high potential to reduce excess
cholesterol without undesirable increase in triglycerides in foam
cells.
In summary, STX4 is a foam cell specific gene regulating
molecule, which showed no significant activity in normal
macrophages. This new LXRa ligand can be applied for
investigating mechanistic aspects of macrophage homeostasis
during (anti-) atherogenic processes, and can be used as a lead
structure for pharmaceutical development.
Discussion
Specific ligands for LXRs are important tools to combat
atherosclerosis and cardiovascular diseases [17]. In this study we
introduced the new LXRa-specific ligand STX4, which has
a stilbenoide structure that is derived from the natural LXR ligand
oxysterol or sterols in general.
Our data suggest that the unique conditional activation
potential of STX4 in diseased foam cells depends on a partner
ligand. As we could show with reporter-gene assays and gene
expression analyses, STX4 cooperates with the synthetic ligand
T09 as well as with natural ligands derived from oxLDL in an
additive manner. An explanation for this behaviour could be
allosteric binding of STX4 to the ligand binding domain. In
addition we assume that a changed set of transcriptional LXR co-
factors in foam cells could be recruited by STX4 and thereby drive
its specific actions. Due to its autoregulatory activation potential,
LXRa has highly increased protein content in foam cells
compared to macrophages [10]. Strikingly, STX4 was not efficient
in activating LXR-target genes in macrophages but only in foam
cells. Lipid loaded foam cells may provide a chemically favourable
hydrophobic, fatty acids rich environment for the STX4
compound. Moreover, the level of LXRa in foam cells in our
experiments was at least 10-fold higher than for LXRb (data not
shown), suggesting that the observed effects of STX4 were mainly
driven by the alpha-subtype. This hypothesis could be confirmed
in reporter gene assays and by trend in LXR knockdown
experiments in cell culture (Figures 1B–C and 2A).
The discussed molecular interaction of STX4 with LXRa could
eventually contribute to the observed conditional activation of
LXRa pathways in diseased foam cells. The STX4 molecule can
be readily applied in cell culture and ex vivo models to study gene
regulation processes and resulting metabolic effects.
Most LXRa/b ligands failed as therapeutic targets due to a lack
of target gene activation potency or adverse side-effects such as
lipogenesis. Due to its more specific anti-atherogenic spectrum the
foam cell specific ligand STX4 holds promise for further
pharmaceutical development. This work will comprise chemical
optimization and modification of the presented STX4 lead
structure, testing of chemical stability and potential side effects
including for example binding tests with nuclear receptors and
other regulating proteins, and applying test panels including
absorption, distribution, metabolism and excretion (ADME), prior
in vivo analyses in model animals. However, the autoregulation of
ligand-activated LXRa in human foam cells varies significantly
from mouse foam cells [10], showing one of the severe limitations
of using mouse models for studying the physiological effects of
drug candidates for treating atherosclerosis [2].
As exemplified in this study, the development of potent
compounds for specifically activating key metabolic nuclear
receptors in diseased but not in normal target cells provides new
avenues for mechanistic studies and for innovative treatment
strategies.
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